Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma: Study of young African American and white women in Atlanta, Georgia

Cancer

Volumn 100, Issue 12, 2004, Pages 2533-2542

  Porter, Peggy L ^a,b   Lund, Mary Jo ^c   Lin, Ming Gang ^a   Yuan, Xiaopu ^a   Liff, Jonathan M ^c   Flagg, Elaine W ^d   Coates, Ralph J ^e   Eley, J William ^c,f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c EMORY UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma; Cell cycle; Race; Young women

Indexed keywords

CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CAUCASIAN; CELL CYCLE; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION; FEMALE; GENE OVEREXPRESSION; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE; RACE DIFFERENCE; TUMOR NECROSIS;

ADULT; AFRICAN AMERICANS; AGE OF ONSET; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GEORGIA; HUMANS; MIDDLE AGED;

EID: 2642575788     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20279     Document Type: Article

References (77)

1. Li C, Malone K, Daling J. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49-56.
2. Shavers V, Harlan L, Stevens J. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer. 2003;97:134-147.
3. Eley J, Hill H, Chen V, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994;272:947-954.
4. Elledge R, Clark G, Chamness G, Osborne C. Tumor biological factors and breast cancer prognosis among white, Hispanic and black women in the United States. J Natl Cancer Inst. 1994;86:705-712.
5. Hunter C, Redmond C, Chen V, et al. Breast cancer: factors associated with stage at diagnosis in black and white women. J Natl Cancer Inst. 1993;85:1129-1137.
6. Zaloznik A. Breast cancer stage at diagnosis: Caucasians versus Afro-Americans. Breast Cancer Res Treat. 1995;34:195-198.
7. Trock B, Rimer B, King E, Balshem A, Cristinzio C, Engstrom P. Impact of an HMO-based intervention to increase mammography utilization. Cancer Epidemiol Biomarkers Prev. 1993;2:151-156.
8. Newman L, Bunner S, Carolin K, et al. Ethnicity related differences in the survival of young breast cancer patients. Cancer. 2002;95:21-27.
9. Chen V, Correa P, Kurman R, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev. 1994;3:127-135.
10. Weiss S, Tartter P, Ahmed S, et al. Ethnic differences in risk and prognostic factors for breast cancer. Cancer. 1995;76:268-274.
11. Sherr C. G1 phase progression: cycling on cue. Cell. 1994;79:551-555.
12. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
13. Keyomarsi K, Tucker S, Buchholz T, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566-1575.
14. Nielsen N, Loden M, Cajander J, Emdin S, Landberg G. G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat. 1999;56:105-112.
15. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients (see comments). Nat Med. 1997;3:222-225.
16. Brinton L, Daling J, Liff J, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87:827-835.
17. Young J, Roffers S, Ries L, Fritz A, Hurlbut A, editors. SEER summary staging manual-2000: codes and coding instructions. Bethesda: National Cancer Institute, 2001.
18. Fritz A, Ries L, editors. The SEER program code manual (3rd edition). Bethesda: National Cancer Institute, 1998.
19. Fleming ID, Cooper JS, Hensen DE, et al., editors. AJCC cancer staging manual (5th edition). Philadelphia: Lippincott-Raven, 1998.
20. Elston C, Ellis I. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
21. Tavassoli FA, Deville P, editors. Pathology and genetics of tumours of the breast and female genital organs. Oxford: Oxford University Press, 2003.
22. Anderson J, Poulson H. Immunohistochemical estrogen receptor determination in paraffin embedded tissue. Cancer. 1989;64:1901-1908.
23. Parl F, Posey Y. Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol. 1988;19:960-966.
24. Shousha S, Stamp T, James K, Alaghband-Zadeh J. Immunohistochemical study of oestrogen receptors in breast carcinomas that are biochemically receptor negative. J Clin Pathol. 1989;43:239-242.
25. Giri D, Goepel J, Rogers K. Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand binding assays and oestrogen receptor immunohistology. J Clin Pathol. 1988;41:444-447.
26. Ellredge R, Clark G, Fuqua S, Yu Y, Allred D. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res. 1994;54:3752-3757.
27. Davidoff A, Herndon J, Glover N. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery. 1991;110:259-264.
28. Purdie C, O'Grady J, Piris J, Wyllie A, Bird C. p53 expression in colorectal tumors. Am J Pathol. 1991;138:807-813.
29. Bartek J, Bartkova J, Vojtesek B, et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer. 1990;46:839-844.
30. Cattoretti G, Becker M, Key G. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168:357-363.
31. Gerdes J, Becker M, Key G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992;168:85-86.
32. Press M, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
33. Ohtsubo M, Theodoras A, Schumacher J, Roberts J, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 1995;15:2612-2624.
34. Motokura T, Bloom T, Kim H, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991;350:512-515.
35. Simpson J, Quan D, O'Malley F, Odom-Maryon T, Clarke P. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol. 1997;151:161-168.
36. WAF1 immunohistochemical expression in breast carcinoma: correlation with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alteration and relapse-free survival. Br J Cancer. 1996;74:208-215.
37. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer. 1996;65:442-445.
38. Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with Stage C prostate carcinoma. J Natl Cancer Inst. 1998;90:916-920.
39. Taylor C, Shi SR, Chaiwun B, Young L, Imam S, Cote R. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol. 1994;25:263-270.
40. Hsu S, Raine L, Fanger H. Use of biotin-avidin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody techniques. Am J Clin Pathol. 1981;75:816-821.
41. Hsu S, Soban E. Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J Histochem Cytochem. 1982;30:1079-1082.
42. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
43. Elmore J, Moceri V, Carter D, Larson E. Breast carcinoma tumor characteristics in black and white women. Cancer. 1998;83:2509-2515.
44. Trock B. Breast cancer in African American women: epidemiology and tumor biology. Breast Cancer Res Treat. 1996;40:11-24.
45. Muss H, Hunter C, Wesley MN, et al. Treatment plans for black and white women with Stage II node-positive breast cancer. Cancer. 1992;70:2460-2467.
46. Ownby H, Frederick J, Russo J, et al. Racial differences in breast cancer patients. J Natl Cancer Inst. 1985;75:55-60.
47. Middleton L, Chen V, Perkins G, Pinn V, Page D. Histopathology of breast cancer among African American women. Cancer. 2003;97(1 Suppl):253-257.
48. Nielson N, Emdin S, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene. 1997;14:295-304.
49. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997;57:1259-1263.
50. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer [see comments]. Nat Med. 1997;3:227-230.
51. Gorgoulis VG, Koutroumbi EN, Kotsinas A, et al. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med. 1998;4:807-822.
52. Geradts J, Wilson P. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol. 1996;149:15-20.
53. Han S, Ahn S, Park K, et al. p16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. Breast Cancer Res Treat. 2001;70:205-212.
54. Milde-Langosch K, Bamberger A, Rieck G, Kelp B, Loning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 2001;67:61-70.
55. Steeg P, Zhou Q. Cyclins and breast cancer. Breast Cancer Res Treat. 1998;52:17-28.
56. Landberg G. Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis. Adv Cancer Res. 2002;84:35-56.
57. Nielsen N, Arnerlov C, Emdin S, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer. 1996;74:874-880.
58. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996;69:92-99.
59. Christov K, Ikui A, Shilkaitis A, et al. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat. 2003;77:253-264.
60. Loden M, Stighall M, Nielsen N, et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene. 2002;21:4680-4690.
61. Herman J, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525-4530.
62. Sherr C. Cancer cell cycles. Science. 1996;274:1672-1677.
63. Serrano M, Hannon G, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/Cdk4. Nature. 1993;366:704-707.
64. Dominguez G, Silva J, Garcia J, et al. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res. 2003;530:9-17.
65. Dublin E, Patel N, Gillett C, Smith P, Peters G, Barnes D. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer. 1998;79:71-75.
66. Hui R, Macmillan R, Kenny F, et al. NK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res. 2000;6:2777-2787.
67. Brawley O. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002;94:471-473.
68. Bradley C, Given C, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94:490-496.
69. Newman L, Mason J, Cote D, et al. African-American ethnicity, socioeconomic status, and breast cancer survival. A meta-analysis of 14 studies involving over 10,000 African-American and 40,000 white American patients with carcinoma of the breast. Cancer. 2002;94:2844-2854.
70. Palmer J, Wise L, Horton N, Adams-Campbell L, Rosenberg L. Dual effect of parity on breast cancer risk in African-American women. J Natl Cancer Inst. 2003;95:478-483.
71. Bernstein L, Teal C, Joslyn S, Wilson J. Ethnicity-related variation in breast cancer risk factors. Cancer. 2003;97:222-229.
72. Pathak D, Osuch J, He J. Breast cancer etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer. 2000;88(5 Suppl):1230-1238.
73. Ries L, Kosary C, Hankey B, Miller B, Clegg L, Edwards B, editors. SEER cancer statistics review, 1973-1996. Bethesda: National Cancer Institute, 1999.
74. Moormeier J. Breast cancer in black women. Ann Intern Med. 1996;124:897-905.
75. Daling J, Malone K, Doody D, Anderson B, Porter P. The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:235-241.
76. Huang W, Newman B, Millikan R, et al. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000;9:65-71.
77. Terry M, Gammon M, Schoenberg J, Brinton L, Arber N, Hibshoosh H. Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev. 2002;11:1100-1103.